Atypical Mycobacteriosis Treatment Market Report 2026

Atypical Mycobacteriosis Treatment Market Overview

• Atypical Mycobacteriosis Treatment market size has reached to $2.4 billion in 2025 • Expected to grow to $3.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: The Growing Demand for Personalized Therapies Is Fueling the Market Growth Due To Advancements In Genomics And Biotechnology • Market Trend: Launch Of Oral Oxaborole Antibiotic MRX-5 To Treat Non-Tuberculous Mycobacterial Infections • North America was the largest region in 2025.

What Is Covered Under Atypical Mycobacteriosis Treatment Market?

Atypical mycobacteriosis treatment refers to the medical management of infections caused by nontuberculous mycobacteria (NTM), which are a group of mycobacterial species that do not cause tuberculosis. These infections can affect various parts of the body, including the lungs, skin, and lymph nodes, and are often more resistant to standard tuberculosis treatments. Treatment typically involves a combination of antibiotics, such as macrolides, rifamycins, and ethambutol, often for an extended duration. The main treatment types for atypical mycobacteriosis include antibiotic therapy, surgical interventions, combination therapy, and supportive care. Antibiotic therapy involves the prolonged use of targeted antibiotics such as macrolides, aminoglycosides, and fluoroquinolones to eliminate or suppress the growth of atypical mycobacteria and prevent recurrence. This approach is used for various types of infections, including atypical mycobacterial lung infections, disseminated infections, and skin and soft tissue infections, and includes routes of drug administration such as oral, intravenous, and topical methods. Treatment is provided to various patient groups, including immunocompromised patients, non-immunocompromised patients, and pediatric patients, and is used by different end-users, such as hospitals, clinics, and home healthcare environments.

What Is The Atypical Mycobacteriosis Treatment Market Growth Forecast?

The atypical mycobacteriosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to growing prevalence of immunocompromised populations, increasing research into novel antimycobacterial agents, rising adoption of personalized treatment approaches, expansion of outpatient and home-based care, improved clinical guidelines for ntm management. Major trends in the forecast period include increasing use of combination antibiotic regimens, rising focus on drug-resistant ntm management, growing adoption of long-duration treatment protocols, expansion of targeted surgical interventions, enhanced emphasis on supportive and adjunctive care.

Global Atypical Mycobacteriosis Treatment Market Segmentation

1) By Treatment Type: Antibiotic Therapy, Surgical Interventions, Combination Therapy, Supportive Care 2) By Type Of Disease: Atypical Mycobacterial Lung Infections, Disseminated Infections, Skin And Soft Tissue Infections 3) By Route Of Administration: Oral, Intravenous 4) By Patient Type: Immuncompromised Patients, Non-Immunocompromised Patients, Pediatric Patients 5) By End Users: Hospitals, Clinics, Home Healthcare Settings Subsegments: 1) By Antibiotic Therapy: Macrolides, Rifamycins, Ethambutol, Aminoglycosides, Fluoroquinolones 2) By Surgical Interventions: Pulmonary Resection, Lymph Node Excision, Skin And Soft Tissue Debridement, Abscess Drainage, Bronchoscopic Interventions 3) By Combination Therapy: Macrolide-Based Triple Drug Regimen, Macrolide Plus Injectable Aminoglycoside, Macrolide Plus Fluoroquinolone And Ethambutol 4) By Supportive Care: Nutritional Support, Respiratory Therapy, Pain Management, Psychological Support

What Are The Drivers Of The Atypical Mycobacteriosis Treatment Market?

The growing demand for personalized therapies is expected to propel the growth of the atypical mycobacteriosis treatment market going forward. Personalized therapies refer to medical treatments tailored to an individual's specific genetic, biological, and environmental factors to optimize effectiveness. The growing demand for personalized therapies is primarily driven by advancements in genomics and biotechnology, as these fields enable the development of treatments tailored to individual genetic profiles, improving efficacy and minimizing side effects. Atypical mycobacteriosis treatment is essential in personalized therapies, as it allows for customized treatment strategies that cater to the specific genetic and clinical characteristics of each patient, leading to more precise and effective care. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the growing demand for personalized therapies is driving the growth of the atypical mycobacteriosis treatment industry. The rising incidence of chronic obstructive pulmonary disease is expected to propel the growth of the atypical mycobacteriosis treatment market going forward. Chronic obstructive pulmonary disease (COPD) refers to a group of progressive lung diseases, including emphysema and chronic bronchitis, that cause airflow blockage and breathing-related problems. The rising incidence of chronic obstructive pulmonary disease (COPD) is primarily due to tobacco smoke, as prolonged exposure to harmful chemicals in tobacco damages the lungs and airways, leading to chronic inflammation and airflow obstruction. Atypical mycobacteriosis treatment supports chronic obstructive pulmonary disease (COPD) management by reducing the bacterial burden and inflammation caused by nontuberculous mycobacteria, which can exacerbate respiratory symptoms and accelerate disease progression. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic obstructive pulmonary disease (COPD) accounted for 3.6% of Australia’s total disease burden and represented 50% of the overall burden from respiratory conditions in 2023, marking an increase from 2.5% of the population living with COPD in 2022, a rise of 44% in disease burden share year over year. Therefore, the rising incidence of chronic obstructive pulmonary disease is driving the growth of the atypical mycobacteriosis treatment industry.

Key Players In The Global Atypical Mycobacteriosis Treatment Market

Major companies operating in the atypical mycobacteriosis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Zydus Pharmaceuticals, Lupin Limited, Gland Pharma Limited, Saphnix Lifesciences Pvt. Ltd., Gentec Pharmaceutical Group, Octavius Pharma Pvt. Ltd.

Global Atypical Mycobacteriosis Treatment Market Trends and Insights

Major companies are operating in the atypical mycobacteriosis treatment market, focusing on developing innovative solutions such as oral oxaborole antibiotics to meet the rising demand for safer, more effective, and long-term treatments for non-tuberculous mycobacterial (NTM) infections. Oxaboroles are a novel class of small-molecule drugs that inhibit bacterial protein synthesis via a boron-based mechanism, offering a distinct mode of action compared to traditional antimycobacterial therapies, reducing toxicity, resistance, and drug–drug interactions. For instance, in January 2025, MicuRx Pharmaceuticals, a China-based biopharmaceutical company, launched MRX-5, an orally bioavailable oxaborole antibiotic developed for NTM infections. The drug demonstrated dose-dependent reductions in lung bacterial load in preclinical models of Mycobacterium abscessus, showed favorable pharmacokinetics, minimal drug-drug interactions, and high oral bioavailability, and is designed for chronic use in patients who require long-term therapy.

Regional Outlook

North America was the largest region in the atypical mycobacteriosis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Atypical Mycobacteriosis Treatment Market?

The atypical mycobacteriosis treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, consultation and care management, surgical intervention, patient education and support services, telemedicine services, inpatient and outpatient care, personalized treatment plans, pharmacovigilance and drug monitoring, nutritional support and counseling, and laboratory and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical mycobacteriosis treatment market also includes sales of clarithromycin, azithromycin, rifampin, ethambutol, amikacin, streptomycin, rifabutin, pyrazinamide, interferons, probiotics, pulmonary inhalers, mucolytics, chronic infection management treatments, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atypical Mycobacteriosis Treatment Market Report 2026?

The atypical mycobacteriosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atypical mycobacteriosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.